Harvey M. Golomb to Cyclophosphamide
This is a "connection" page, showing publications Harvey M. Golomb has written about Cyclophosphamide.
Connection Strength
0.217
-
Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)--effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma. Cancer Treat Rep. 1976 Sep; 60(9):1225-30.
Score: 0.034
-
The impact on survival by adjuvant chemotherapy and radiation therapy in stage II non-small-cell lung cancer. Am J Clin Oncol. 1992 Oct; 15(5):405-11.
Score: 0.026
-
Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP. Leukemia. 1990 Feb; 4(2):127-31.
Score: 0.021
-
High-dose, multiple-alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non-small cell lung cancer. Cancer. 1989 Jan 15; 63(2):238-42.
Score: 0.020
-
A 10-year experience with combined modality therapy for stage III small cell lung carcinoma. Cancer. 1986 Nov 15; 58(10):2177-84.
Score: 0.017
-
The treatment of histiocytic lymphoma. Semin Oncol. 1980 Sep; 7(3):302-9.
Score: 0.011
-
Diagnosis, staging, and treatment of the malignant lymphomas. Compr Ther. 1980 Jul; 6(7):48-56.
Score: 0.011
-
Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP). JAMA. 1978 Dec 15; 240(25):2743-6.
Score: 0.010
-
Hexamethylmelamine, bleomycin, and CCNU chemotherapy for patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung unresponsive to cyclophosphamide, adriamycin, methotrexate, and procarbazine. Cancer Treat Rep. 1978 Apr; 62(4):567-9.
Score: 0.009
-
Combined modality therapy for stage IIIMO non-oat cell bronchogenic carcinoma. Cancer Treat Rep. 1978 Mar; 62(3):327-32.
Score: 0.009
-
Letter: Prolonged survival of patients with extensive oat cell carcinoma treated with radiotherapy and cyclophosphamide (NSC-26271), vincristine (NSC-67574), and methotrexate (NSC-7040). Cancer Treat Rep. 1976 Mar; 60(3):221-3.
Score: 0.008
-
Combination chemotherapy of lymphomas other than Hodgkin's disease. Ann Intern Med. 1974 Nov; 81(5):601-8.
Score: 0.007
-
The non-Hodgkin's lymphomas: a review. Rev Bras Pesqui Med Biol. 1974 Mar-Apr; 7(2):123-31.
Score: 0.007
-
Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, oncovin, methotrexate, leucovorin, cytosine arabinoside): a 10-year experience in a single institution. J Clin Oncol. 1985 Dec; 3(12):1596-604.
Score: 0.004
-
CAMP chemotherapy for metastatic non-oat cell bronchogenic carcinoma. A 7-year experience (1975-1981) with 160 patients. Cancer. 1985 Nov 15; 56(10):2385-90.
Score: 0.004
-
Long-term survival of patients with localized diffuse histiocytic lymphoma. J Clin Oncol. 1985 Oct; 3(10):1309-17.
Score: 0.004
-
Metastatic non-small cell bronchogenic carcinoma: a randomized trial of sequential vs combination chemotherapy. Eur J Cancer Clin Oncol. 1983 Jan; 19(1):33-8.
Score: 0.003
-
VP16-213 in combined modality treatment of small cell carcinoma of the lung. Eur J Cancer Clin Oncol. 1982 Apr; 18(4):343-6.
Score: 0.003
-
Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med. 1980 Jun; 92(6):785-90.
Score: 0.003
-
Pathologic stage I and II Hodgkin's disease, 1968--1975: relapse and results of retreatment. Cancer. 1979 Jul; 44(1):72-9.
Score: 0.003
-
Letter: Chemotherapy of advanced histocytic lymphomas. Lancet. 1975 May 17; 1(7916):1136.
Score: 0.002